Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Hims & Hers Health stock tanks
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's Q3 2024 revenue is expected to exceed projections as concerns rise over compounded GLP-1 medications.
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is over
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 medications.
Hims & Hers Health Stock Falls as FDA Drops Eli Lilly Weight-Loss Drugs From Shortage List
Key Takeaways Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration (FDA) said Eli Lilly's popular weight-loss drugs are no longer on its list of drugs in short supply. The FDA allows companies to produce compounded copycat drugs when the originals are hard to obtain,
Nvidia, Levi Strauss & Co & Hims & Hers Health Inc
3-Stock Lunch: Nvidia, Levi Strauss & Co & Hims & Hers Health Inc
Quint Tatro, Joule FInancial president, joins 'Power Lunch' to discuss stock plays for three stocks.
Why Did Hims & Hers Health Inc (HIMS) Stock Surge 9.02% Last Week?
On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $17.77 which represents a slight increase of $0.06 or 0.34% from the prior close of $17.71. The stock opened at $17.
These Stocks Are Moving the Most Today: EVgo, Levi Strauss, Humana, Hims & Hers, Nvidia, Stellantis, and More
EVgo stock surges after the company receives a $1 billion Energy Department loan commitment, Levi Strauss tumbles after cutting its fiscal-year revenue outlook, and Humana extends losses.
1d
on MSN
For Hims & Hers Stock, GLP-1 Giveth and GLP-1 Taketh Away
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
1d
Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...
2d
Weight Loss Solutions for Front-Line Heroes: Hims & Hers Tackles Barriers
Hims & Hers is making GLP-1 weight loss medications more accessible with a 50% discount for front-line heroes. Mihir Gandhi ...
2d
These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.
9d
Hims & Hers: The Gift That Keeps On Giving
Hims & Hers stock is currently in the middle of a deep drawdown. Read why I maintain my strong buy rating on HIMS stock.
8d
Hims & Hers Health's Options Frenzy: What You Need to Know
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Food and Drug Administration
Homs
Feedback